New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), Campus Crest Communities Inc (NYSE:CCG), ShoreTel, Inc (NASDAQ:SHOR), Dyax Corp (NASDAQ:DYAX)
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) showed a volume of 1.49 million shares by the end of last trade whereas the average volume of the stock remained 1.41 million shares. The stock opened the session at $1.89 but then moved to $1.75. At that price, the stock showed a negative performance of -6.42%. Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
Will LXRX Get Buyers Even After The Recent Rally? Find Out Here
Campus Crest Communities Inc (NYSE:CCG) opened the session at $9.21 and closed the session at $9.14. The stock showed a negative performance of -0.22% in previous trading session. Traded with volume of 1.48 million shares in the prior session and the average volume of the stock remained 587,005 shares. Campus Crest Communities, Inc. is a self-managed, self-administered and vertically-integrated developer, builder, owner and manager of purpose-built student housing properties in the United States. The Company operates in two segments: student housing operations and development,
Has CCG Found The Bottom And Ready To Gain Momentum? Find Out Here
ShoreTel, Inc (NASDAQ:SHOR) opened the session at $8.31 and closed the session at $7.97. The stock showed a negative performance of -4.09% in previous trading session. Traded with volume of 1.45 million shares in the prior session and the average volume of the stock remained 602,697 shares. The beta of the stock remained 1.36. ShoreTel, Inc. is a provider of business communication solutions. The Company’s unified communications (UC) and contact center solutions are based on its Internet protocol (IP) business phone system (IP-PBX). It offers organizations of all sizes integrated voice, video,
Why Should Investors Buy SHOR After the Recent Fall? Just Go Here and Find Out
Dyax Corp (NASDAQ:DYAX) the stock decreased -4.53% and finished the session at $8.43. Traded with volume of 1.45 million shares in the prior session and the average volume of the stock remained 1.04 million shares. The beta of the stock remained 1.69. Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema.
Will DYAX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)